



PRESS RELEASE

Stockholm June 30, 2023

Jan Nilsson leaves his position as CEO of CombiGene COO Peter Ekolind takes over as new CEO on September 1, 2023

CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as CEO of the Company on September 1, 2023, when the Company’s current COO Peter Ekolind will take over as CEO in accordance with current succession plan.

Peter Ekolind has extensive leadership experience from the pharmaceutical and medtech industry. Many years of experience from a variety of positions have given Peter solid knowledge in product development, sales, marketing, preclinical development and GMP manufacturing. Peter has held several senior positions such as Business Area Manager, COO and CEO. He has served in a variety of firms, ranging from large multi-international companies to small development companies, with roles in business development, capitalization, internationalization, change management, innovation issues, public procurement, negotiations, and research collaborations with universities. Peter has been Chief Operating Officer at CombiGene since September 2022.

“Let me start by thanking Jan for his fantastic contributions to CombiGene, not least in connection with the agreement with Spark Therapeutics. During his time as CEO, CombiGene has evolved from a small company with one project to the CombiGene we see today – a platform company with several active projects, intense business development, a strong reputation, and broad interactions with the international gene therapy community. At the same time as I thank Jan, I would like to welcome Peter Ekolind as the new CEO of CombiGene”, says CombiGene’s Chairman of the Board Jonas Ekblom. “For me as Chairman of the Board of CombiGene, it is very satisfying that we are now carrying out this change of CEO in accordance with pre-established succession plan. Together with the rest of the Board and all employees at CombiGene, Peter Ekolind and I are looking forward to continue the development of the Company into an increasingly stronger and attractive gene therapy company,” Jonas concludes.

Jan Nilsson will continue to assist CombiGene on a consultancy basis, including the Company’s involvement in the newly formed CCRM Nordic AB, where Jan was recently elected Chairman of the Board.

This information is information that CombiGene AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, June 30, 2023, 08:00 CEST.

About CombiGene AB

CombiGene’s vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene’s business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations.

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.

The company is public and listed on the Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.



For more information:

CombiGene AB (publ)

Jonas Ekblom, Chairman of the Board

Phone: +46 (0)8 35 73 55

jonas.ekblom@promorepharma.com

Please read *Ingeneious*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *Ingeneious* and press releases are available at www.combigene.com